Cytophenix is developing rapid antimicrobial susceptibility tests to identify the most effective antibiotics.
Cytophenix has raised $855K in total funding. The most recent round was Pre-Seed. The last funding was announced in October 2025.
Cytophenix's investors include CSIRO, CUREator.
Cytophenix is headquartered in Perth, Australia.
Cytophenix is developing rapid antimicrobial susceptibility tests to identify the most effective antibiotics.
Cytophenix is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cytophenix — Funding & Investors." VCBacked, October 29, 2025, https://www.vcbacked.co/company/cytophenix. Accessed August 14, 2026.
VCBacked. (2025). Cytophenix — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/cytophenix
{{cite web |title=Cytophenix — Funding & Investors |url=https://www.vcbacked.co/company/cytophenix |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated